W. Floyd

Enhancing radiotherapy response via intratumoral injection of the TLR9 agonist CpG to stimulate CD8 T cells in an autochthonous mouse model of sarcoma

This study shows that combining radiotherapy with CpG, a TLR9 agonist, enhances tumor response in a mouse sarcoma model by boosting CD8 T cell activity.

Loss of function of Atrx leads to activation of alternative lengthening of telomeres in a primary mouse model of sarcoma

This study shows that loss of Atrx in a mouse sarcoma model activates the ALT telomere maintenance pathway independently of telomerase, leading to telomere instability and APB formation.

Atrx deletion impairs cGAS-STING signaling and increases response to radiation and oncolytic herpesvirus in sarcoma

This study shows that ATRX deletion in sarcomas increases sensitivity to radiation and oncolytic herpesvirus by impairing cGAS-STING signaling and reducing immune response.

Loss of the chromatin remodeler, ATRX, promotes aggressive features of osteosarcoma with increased NF-κB signaling and integrin receptor binding

This study shows that loss of ATRX in osteosarcoma promotes aggressive tumor features through NF-κB signaling and integrin receptor binding, suggesting new therapeutic targets.

Disruption of oncogenic targeting by ISWI via phosphorylation of a prion-like domain

The paper shows that ionizing radiation disrupts oncogenic interactions between the fusion oncoprotein FUS-CHOP and the chromatin remodeler ISWI via phosphorylation of FUS-CHOP's prion-like domain, explaining radiation sensitivity in myxoid liposarcoma.